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Rett Syndrome was long considered to be simply a disorder of postnatal development, with phenotypes that manifest only late in
development and into adulthood. A variety of recent evidence demonstrates that the phenotypes of Rett Syndrome are present at
the earliest stages of brain development, including developmental stages that define neurogenesis, migration, and patterning in
addition to stages of synaptic and circuit development and plasticity. These phenotypes arise from the pleotropic effects of MeCP2,
which is expressed very early in neuronal progenitors and continues to be expressed into adulthood. The effects of MeCP2 are
mediated by diverse signaling, transcriptional, and epigenetic mechanisms. Attempts to reverse the effects of Rett Syndrome need
to take into account the developmental dynamics and temporal impact of MeCP2 loss.
1. Introduction
Rett Syndrome (RTT) is a developmental neurological disor-
der that affects 1 in every 10,000–15,000 live births in the US
[1]. The genetic origin of RTT, in ∼90% of patients, has been
traced to sporadic loss-of-functionmutations in the X-linked
gene MECP2 coding for methyl CpG-binding protein 2,
mainly localized to methylated pericentric heterochromatin
[2]. Clinical features of the disorder involve marked devel-
opmental regression, progressive loss of acquired motor and
language skills, the acquisition of stereotyped repetitive hand
movements, muscle hypotonia, autonomic dysfunctions, and
severe cognitive impairment.
MeCP2 is an epigenetic modulator of gene expression. It
acts as both a transcriptional activator and repressor [3, 4], in
addition to regulating gene expression posttranscriptionally
via microRNA- (miRNA-) processing machinery [5] and in
an activity-dependent manner to regulate synaptic activity
[6]. The binding interaction between MeCP2 and DNA is
governed by a variety of genetic and epigenetic factors such
as the length of the DNA, nearby sequences, and methylation
patterns [3, 7, 8]. MeCP2 is a known binding partner of
5-methylcytosine (5mC) at CpG dinucleotides throughout
the genome, resulting in transcriptional repression in these
regions [9]. However, MeCP2 is also the predominant 5-
hydroxymethylcytosine- (5hmC-) binding protein in the
brain. Enrichment of 5hmC is linked to highly expressed
genes [10, 11] in the absence of 5mC, suggesting that, in the
context of this binding interaction, MeCP2 facilitates tran-
scription [11]. Of note,MeCP2 is itself subject tomethylation-
dependent regulation, disruptions which have been linked to
autism [12]. Thus, epigenetic modifications can regulate both
the expression of MeCP2 and its downstream binding part-
ners.
Alternative splicing ofMecp2/MECP2 generates twomain
isoforms that differ exclusively at the N-terminus [13, 14]:
MeCP2 e1, the predominant isoform in the brain [13–16], and
MeCP2 e2, which displays a later expression onset during
mouse brain development [17]. The two isoforms exhibit
differential temporal and region-specific differences in their
expression profiles in the brain and both contribute to
neurological function and gene expression patterns [18–20].
The ratio of splice variants differs in a temporal- and cell
type-specific manner, suggesting dynamic regulation of their
expression and nonredundant functionality in the distinct
stages of neurogenesis and adulthood [15, 17, 18, 21]. Whereas
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MeCP2 e1 has been shown to be the isoform most relevant
to RTT pathogenesis [20], MeCP2 e2 interacts with forkhead
protein FoxG1, which promotes neuronal survival and mat-
uration and in which mutations can also cause RTT [22].
The physiological significance of these two isoforms is not
fully understood.Manipulations of independent isoforms in a
cell type-specific manner are required in order to reveal their
respective contributions to activity-dependent functions of
MeCP2.
MeCP2 expression affects successive stages of brain devel-
opment including prenatal neurogenesis, postnatal devel-
opment of synaptic connections and function, experience-
dependent synaptic plasticity, and maintenance of adult neu-
ral function including sensory integration [1, 23, 24]. MeCP2
critically maintains synaptic excitation (E) and inhibition
(I), which are fundamental to the function of brain circuits
and are often disrupted in neurological disorders including
RTT [23, 25]. Additionally, MeCP2 has a remarkably diverse
pool of binding partners and downstream targets [26, 27].
This functional and binding complexity, in combination with
the domain-specific functionality of the MeCP2 protein [28,
29], confers a pleiotropic effect across age- and cell type-
specific backgrounds [7]. Accordingly, different mutations
in MeCP2 result in a wide range of phenotypic variability
and severity in RTT patients [30], necessitating context-
dependent mechanistic insights into MeCP2 function.
Transgenic mouse models that harbor cell type-specific
mutations inMeCP2 have shed light on our understanding of
RTT pathogenesis in the brain. Expression of MeCP2 under
the CamKII or neuron-specific enolase promoter does not
prevent the appearance of most RTT phenotypes, suggesting
a more complex network of involvement for MeCP2 [31].
Interestingly, mice lacking MeCP2 exclusively in GABAergic
neurons recapitulate many RTT features [32], and deletion
of MeCP2 in the parvalbumin- (PV-) expressing subset of
GABAergic neurons abolishes experience-dependent critical
period plasticity in the absence ofmost RTT phenotypes [33].
The restoration of MeCP2 exclusively in astrocytes results
in a non-cell-autonomous ameliorative effect on neurons in
vivo [34], whereas RTT microglia exhibit adverse non-cell-
autonomous effects on WT neurons in vitro [35]. In spite of
their differing roles and effects on downstream gene regu-
lation [18], transgenic expression of either the MeCP2 e1 or
MeCP2 e2 splice variant has been shown to prevent the devel-
opment of a number of RTT phenotypes in a mouse model
lacking MeCP2. However, many abnormalities were only
partially prevented, negating the notion that both transcripts
are capable of acting independently to fulfill all of the roles of
MeCP2 [36]. Accordingly, another study demonstrated that a
point mutation in the MeCP2 e1 splice variant is sufficient to
recapitulate many RTT phenotypes observed in MeCP2 KO
mice [20]. Whereas the complexity that underlies the roles of
MeCP2 will not be resolved with a single mouse model, each
contributes a piece to the larger puzzle that representsMeCP2
functionality.
Similar to loss-of-function mutations in MECP2, the
duplication ofMECP2 also results in a progressive neurolog-
ical disorder that includes stereotypic and repetitive hand or
bodymovements, epilepsy, spasticity, and a severe syndromic
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Figure 1: MeCP2 influences multiple features of brain development
and function, at a variety of time points as its expression increases
and is maintained. Thus, prenatal and postnatal brain development,
as well as adult function, are all potentially affected in Rett Syn-
drome.
form of intellectual disability in male patients [37]. Recent
studies show that the neurological dysfunctions in MECP2
duplication syndrome are reversible in adult symptomatic
mice and correction of MeCP2 levels genetically or by using
antisense oligonucleotides largely restoresmolecular, electro-
physiological, and behavioral deficits [38].
Traditionally, the dynamic time-course of RTT is thought
to involve a period of apparently normal early development
followed by profound neurological regression—a defining
feature of RTT—and subsequent stabilization or partial
recovery. However, our understanding of the disease ini-
tiation and progression and the ways in which MECP2
impacts distinct phases of neurodevelopment is gradually
evolving. In recent years, there has been a gradual shift in our
understanding of atypical regression in RTT patients, with
growing evidence of prenatal and early postnatal develop-
mental abnormalities resulting in defects in the establishment
and refinement of early neural circuits and, later, cortical plas-
ticity (Figure 1). In this review, we aim to summarize recent
findings and argue thatMECP2 serves distinct, discrete func-
tions throughout developmental and adult stages, integrating
genomic and environmental signals in a context-dependent
manner.
2. Deficits in Early Neurogenesis
Early work in mouse models on the function of MeCP2
reported a pattern of expression limited to the neural lineage,
with low expression in neuroblasts and a progressive increase
during embryonic and postnatal development. Such findings
led to the belief that MeCP2 is predominantly involved
in the maturation and maintenance of neuronal function,
as opposed to early cell fate decisions, and were further
supported by a lack of phenotype observed with respect to
differentiation inMeCP2-null neural progenitor cells (NPCs)
[39].
Evidence has since demonstrated that, whereas MeCP2
expression increases postmitotically, bothmRNAand protein
can be detected throughout the majority of the mouse and
human lifespan, including embryonic stages during which
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neurogenesis occurs [21, 40–44]. MeCP2 protein expression
does indeed increase after neuronal differentiation, when the
vastmajority of RTT phenotypes have been described. Exper-
iments designed to determine isoform-specific expression
have detected MeCP2 e1 protein in the mouse hippocampus
as early as E14, whereas MeCP2 e2 was first detected at E18
[17]. Samples younger than E14 were not analyzed in this
study, and thus these results do not preclude the possibility of
expression at earlier embryonic stages. MeCP2 e1 expression
increased until it reached a plateau at P7–P21. MeCP2 e2
expression overlapped with MeCP2 e1 after E18, albeit at a
decreased level. As the gestational period of synaptogenesis
overlaps with that of neuronal migration in human develop-
ment [45], it stands to reason that MeCP2, known to regulate
synaptic development [46–48] and cell guidance and laminar
organization in the olfactory system [49], may contribute
to the processes of cell fate specification and migration in
the developing brain, especially the cortex. Accordingly, the
landscape of clinical literature has been shifting to suggest an
earlier onset of symptoms in RTT patients [50–54].
3. Cell Fate and Signaling Pathways
Expression of MeCP2 during early neurogenesis suggests a
consequent role for the protein during this critical devel-
opmental time point. Neurogenic functions of MeCP2 have
indeed since been demonstrated in mouse, whereby embry-
onic NPCs overexpressing MeCP2 exhibited a heightened
neural identity in vitro [55]. Conversely, embryonic NPCs
extracted from mice lacking MeCP2 exhibited a more
proliferative—as opposed to late postmitotic—identity and
revealed morphological alterations as early as 3 days in vitro
(DIV) [44]. A human patient-derived induced pluripotent
stem cell (iPSC) model of Rett Syndrome expressing a de
novo frame-shift mutation in exon 4 (c.806delG) illustrated
a parallel role for MeCP2 in the promotion of neural identity
inwhich neural stem cells lackingMeCP2 exhibited increased
astrocytic differentiation in vitro [56]. Mesenchymal stem
cells (MSCs) isolated from a Rett patient harboring a dif-
ferent de novo mutation (del 1164-1207) also demonstrated
impaired neural differentiation in vitro, which resulted in a
reduced percentage of NeuN-expressing cells and increased
senescence [57]. Roles forMeCP2 in determining neurogenic
potential have been reported in Xenopus [58], zebrafish [59,
60], and chick [61] embryos.
Mechanisms underlying the function of MeCP2 with
respect to early cell fate decisions are largely unknown. Neu-
rogenic signaling cascades such as theNotch-Delta and PI3K-
Akt pathways have been demonstrated to coordinate with
MeCP2 throughout various time points including neurogen-
esis. Phosphorylation of MeCP2 at Serine421 (S421)—known
to regulate gene transcription and synaptic development in
an activity-dependent manner [62]—has since been shown
to modulate the balance between proliferation and differen-
tiation in NPCs isolated from the adult mouse hippocampus.
Evidence suggests that the Notch-Delta signaling pathway,
mediated via MeCP2-S421 phosphorylation, may serve as
the hub linking MeCP2 to neural cell fate decisions in adult
NPCs [63]. Experiments performed in Xenopus embryos, in
which MeCP2 is expressed and is critical for neurogenesis,
have demonstrated that the Notch-Delta signaling pathway
regulates the patterning of primary neuronal differentiation
in conjunction with MeCP2 binding. A complete lack of
MeCP2 protein resulted in a decrease in the number of
neuronal precursors, whereas expression of a truncated form
of MeCP2 often found in Rett Syndrome patients—R168X—
resulted in an increase in the number of neuronal precur-
sors relative to WT embryos [58]. This phenotypic variety
observed as a result of varying dosages and mutations of
MeCP2 is echoed throughout the experimental and clinical
literature [30, 52, 53, 64].
The PI3K-Akt signaling pathway is implicated in a wide
range of cellular functions including cell cycle and transcrip-
tional regulation [65]. The pathway has also been shown to
regulate key neurological processes such as synaptic trans-
mission [66] and neurodegeneration [67, 68] and is impli-
cated in a range of neurological diseases and disorders such as
spinocerebellar ataxia type 1 [67], Huntington’s disease [68],
amyotrophic lateral sclerosis (ALS) [69], and RTT [4, 70–72].
The majority of studies performed in RTT models, including
those listed above, have examined the contribution of the
PI3K-Akt pathway to disease effects and rescue in mature
neurons. Whereas PI3K-Akt signaling has been shown to
promote adult neurogenesis in the context of exercise enrich-
ment [73], traumatic brain injury recovery [74], and surgical
denervation [75], roles for PI3K-Akt signaling have also been
demonstrated throughout embryonic neurogenesis in mouse
[76], Xenopus [77], and zebrafish [78]. However, the precise
roles of PI3K-Akt signaling in embryonic neurogenesis in the
context of RTT have yet to be elucidated.
4. microRNAs and MeCP2
microRNAs (miRNAs) finely regulate genetic networks
throughout the course of brain development and, with
astounding complexity, act as critical determinants of early
neurogenic activities such as cortical patterning and activ-
ity development, cellular subtype specification, and neu-
ronal differentiation [79–81]. They are themselves subject to
upstream epigenetic regulation; many are indeed targets of
MeCP2 [82] or, as in the case of miR-132, act in a feedback
loop as both target and regulator to maintain MeCP2 levels
[83]. miR-132 has in turn been shown to promote postnatal
neurogenesis and synaptic integration in neurons of the
olfactory bulb [84]. Another brain-enrichedmiRNA target of
MeCP2, miR-137, has been shown to regulate neuronal mat-
uration and dendritogenesis in the postnatal hippocampus
[85] and tomodulate proliferation and differentiation in adult
neurogenesis [82]. Moreover, miR-137 has been shown to
negatively regulate neural stem cell proliferation and promote
differentiation in the embryonic mouse brain [86]. miR-
199a has been demonstrated as a link between MeCP2 and
the mTOR pathway [87], previously implicated in RTT [72].
MeCP2 facilitates the postprocessing of miR-199a, which
positively regulates mTOR signaling. Notably, exogenous
miR-199a ameliorates several impairments in RTT neurons
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and the genetic deletion of miR-199a-2 results in decreased
mTOR activity in the brain and the recapitulation of sev-
eral RTT phenotypes [87]. MeCP2 is known to influence
the production of growth factors such as BDNF and IGF1—
the latter via a miRNA-mediated pathway downstream of
BDNF [88]. Many pathways and loops that determine the
process of neurogenesis are maintained by the concerted
regulation of miRNAs and MeCP2. As such, they provide
insight into potential avenues by which MeCP2—or the lack
thereof—can influence the developing cortex.
5. Deficits in Neuronal Migration and
Cortical Patterning
Functions of MeCP2 during early neurogenesis result in
immediate and long-term effects on neuronal migration and
cortical patterning. Migration begins at gestational week 8
in humans and at E11 in mouse, at which point neural
progenitors proliferating within the ventricular zone that
lines the cerebral ventricles begin to differentiate to form
the cortical laminae [45, 89]. Postmitotic cells migrate over
radial glial scaffolds to form the discrete layers of the cerebral
cortex in an inside-first, outside-last temporal pattern. Deep-
layer cortical neurons are born first and passed by newly born
neurons migrating to upper layers.This process is spatiotem-
porally governed by a variety of signaling, transcriptional,
and epigenetic mechanisms [90–92]. Aberrant regulation
of the proliferation and differentiation of neural stem cells
results in a range of cortical dysplasias and is associated with
many neurological and neuropsychiatric disorders including
Alzheimer’s disease, schizophrenia, and ASDs [93].
Early work demonstrated morphological cortical deficits
in 8-week-old MeCP2−/Y mice including reduced thickness
and increased cell density in neocortical layers; due in part
to the belief that MeCP2 was not expressed early on, these
alterations were believed to be a result of reduced cell size
and complexity as opposed to deficits in corticogenesis [39].
Cerebellar expression profiling performed alongside chro-
matin immunoprecipitation in MeCP2-deficient mice has
since revealed increased expression of Reln—encoding the
extracellular signaling protein Reelin, known to be essential
for proper neuronal lamination [94]. Accordingly, recent
evidence has demonstrated that mouse NPCs lackingMeCP2
exhibit delayed corticogenesis with respect tomigration from
the subventricular and ventricular zones into the cortical
plate [44]. These findings suggest a need for a thorough eval-
uation of the role ofMeCP2 in cortical migration and lamina-
tion, as layering deficits observed at postnatal time points in
RTTmay result from combinatorial deficits in cortical devel-
opment and maintenance.
6. Deficits in Synaptic Transmission and
Plasticity during Postnatal Development
Alongwith deficits in early neurogenesis and cortical pattern-
ing, MECP2 has been shown to play a key role in synaptic
maturation and plasticity. Mutant mouse models have been
generated with a global deletion of MeCP2 (MeCP2−/Y) from
all neurons and selectively from specific cellular subtypes
including various neuronal subtypes and astrocytes. These
models have served as a robust starting point in which to
study the common principles underlying synaptic defects in
RTT. They provide unique insight into the genetics that
determine cell type-specific contributions to pathogenesis.
Functional defects in synaptic transmission have been
investigated in an Mecp2 global deletion model in which
cortical connections were found to have weaker excitatory
synaptic transmission and lower levels of basal activity [1, 95–
98], reminiscent of an immature circuit. Cellularmechanisms
of long-term plasticity, considered the functional basis of
learning and memory, have also been found to be impaired
in Mecp2 mutant animals [2, 99, 100]. The majority of these
early studies have used brain slice preparations, recording
synaptic transmission including miniature synaptic currents
and synaptic plasticity deficits. Similar to deficits in excitatory
transmission, deletion ofMecp2 from all forebrain GABAer-
gic interneurons also recapitulates key features of RTT, sug-
gesting that inhibition plays a crucial role in RTT pathophysi-
ology.This includes reducedGABA synthesis, Gad1 andGad2
levels, reduced miniature inhibitory postsynaptic currents
(mIPSCs), and an array of behavioral deficits including
EEG hyperexcitability and severe respiratory dysrhythmias
[3, 4, 32]. Anatomical studies have reported enhanced PV+
neuronal puncta andhyperconnected PV+ circuitry inmouse
visual cortex, suggesting that these microcircuits contribute
to enhanced inhibition in MeCP2−/Y mice [5, 101]. This
altered inhibitionmediated by PV+ neurons, which regulates
the initiation and termination of the critical period, has been
proposed to alter the timing of critical period plasticity in
RTT [6, 102]. Functional studies, however, have consistently
reported decreased inhibitory function including reduced
mIPSCs in CA3 pyramidal neurons of MeCP2−/Y mice [3, 7,
8, 103]. Although the density and intrinsic membrane prop-
erties of PV+ and somatostatin (SST)+ interneurons were
not affected in MeCP2−/Y mice, miniature excitatory postsy-
naptic currents (mEPSCs) were found to be smaller and less
frequent in fast-spiking PV+ neurons, suggesting impaired
glutamatergic drive specifically onto this interneuron popu-
lation compared to SST+ neurons [103]. Studies in slices have
also reported a reduction in mEPSC amplitudes and a deficit
in excitatory pathways, in the absence of change in mIPSC
amplitude or frequency [95, 104]. These results are consistent
with the decreased visually evoked responses found in PV+
interneurons in mouse visual cortex in vivo [33]. Interest-
ingly, recent studies have highlighted the differential effects
of subtype-specific Mecp2 deletion on GABAergic inhibi-
tion regulating nonoverlapping neurological symptoms:mice
lacking MeCP2 in PV+ neurons showed sensory, motor,
memory, and social deficits, whereas those lacking in SOM+
neurons exhibited seizures and stereotypies [105], further
elucidating the complex regulation of inhibition and their
disruption in RTT [23].
Taken together, these features indicate that RTT is a com-
plex disorder that arises from an imbalance of excitation and
inhibition and a failure of brain circuitry to attain a mature
state [9, 23]. Many of these defects can have a strong early
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developmental, even prenatal, component (Figure 1) when
the brain fails to attain “phenotypic checkpoint” signatures
and in turn provides faulty functional feedback that influ-
ences gene expression [106] and network malfunction [107].
A coherent set of physiological measurements using in vivo
awake animalmodels of global and neuronal subtype-specific
Mecp2 deletion remains necessary to measure and evaluate
functional defects in the synaptic balance of excitation and
inhibition. Another important consideration in this regard
is to extend findings of cell-specific and synaptic defects
in mouse models to identify biomarkers of RTT in human
patients. Several recent studies are bridging this gap. Visual
evoked potential (VEP) recordings in response to high-
contrast oriented gratings have previously revealed loss of
visual acuity in adultMecp2mutantmice at the onset of RTT-
like symptoms during critical periods of mouse visual cortex
development [101], strongly suggesting that vision may serve
as a biomarker of altered cortical function in RTT. Recent
work has demonstrated that RTT patients exhibit a similar
decrease in VEP amplitude and a reduction in visual spatial
acuity that is impacted byMECP2mutation type [108].
7. Deficits in Adult Maintenance and Function
The onset of symptoms during early life in RTT patients,
in conjunction with findings from mouse models suggesting
neurodevelopmental abnormalities in RTT, has raised the
question whether Mecp2 function is necessary for inte-
grative function in the adult brain. One study used an
inducible knockout approach to delete Mecp2 by crossing a
floxedMecp2 allele mice with a tamoxifen-inducible Cre-ER
expressing allele in adult mice (P60 or older) following nor-
mal development [109]. This late-deletion of Mecp2 recapit-
ulated key germline knockout phenotypes including abnor-
mal gait, hind-limb clasping, motor abnormalities, impaired
nesting ability, and impaired learning and memory, further
underscoring the importance ofMecp2 in adult neurological
function [109]. Interestingly, this adult deletion recapitulated
an epigenetic memory clock, suggesting a mechanism that
extends—or is independent from—its early global genetic
regulation [110].
Similar to behavioral deficits, the physiological response
features of adult Mecp2-deleted neurons have also been
characterized in vivo [111]. CRISPR-associated endonuclease
(Cas) 9 has been used to introduce frame-shifting, inser-
tion/deletion (INDEL) mutations that are targeted to the
Mecp2 locus using specific guide RNAs (gRNAs) via adeno-
associated viral (AAV) vectors [112]. In vivo genome-editing
resulted in ∼68% of targeted cells containing INDEL muta-
tions with a >60% reduction in MeCP2 protein levels [111].
Stereotactic injection of AAV-SpCas9 and gRNA targeting
Mecp2 into the superficial layers of mouse primary visual
cortex followed by two-photon guided targeted electrophys-
iological recordings from genome-edited neurons revealed
altered integrative visual responses, further emphasizing the
maintenance role of Mecp2 in the adult brain after normal
developmental milestones have been achieved.
8. Reversal of Functional and
Behavioral Deficits in RTT
One of the key discoveries in RTT has been the recovery of
function following reactivation of endogenous Mecp2 [113,
114]. This striking finding, an important feature not only of
RTT but perhaps also of neurodevelopmental disorders in
general, suggests that the neurodevelopmental pathology is
reversible.
The phenotypic reversibility of advanced neurological
phenotypes in both immature and mature adult animals
shows that reactivation of the MeCP2 protein even at late
stages of the disorder can partially rescue the mutant phe-
notype [113, 115]. Systemic delivery of MeCP2 cDNA via
AAV9, under control of a fragment of its own promoter
(scAAV9/MeCP2), has been shown to significantly rescue
behavioral and cellular deficits when administered systemi-
cally into female RTT mice [116]. Proposed as a model for
gene therapy, the retroviral-mediated overexpression of the
MeCP2 e1 isoform in neural stem cells taken from Mecp2
heterozygous mice was shown to promote dendritic branch-
ing in vitro [117]. Perhaps more practically, pharmacological
manipulations, such as the treatment ofMecp2 null mice with
recombinant human IGF1 (rhIGF1) or a peptide fragment
of IGF1, also resulted in a partial rescue of synaptic defects
and cortical excitatory synaptic transmission, in addition to
restoring activation of signaling pathway proteins [70, 71].
These studies argue that the brain circuits involved in neural
processing may not functionally decline but rather remain in
a labile, immature state; their subsequent activation by the
reintroduction of Mecp2 [113, 115] or by pharmacological
manipulations to activate downstream signaling pathways
[70, 71] is an important measure to ameliorate the syndrome’s
consequences.
9. Conclusions
The fluidity with which MeCP2 regulates the genomic land-
scape renders a uniquely moving target that has proven
difficult to fully understand. Amongst many factors to be
taken into account when attempting to attribute mechanistic
function to MeCP2 (e.g., cell type, mutation and associated
functional domain, and range of downstream targets), it is
crucial to consider the time point in question. Deletion of
MeCP2 results in a wide and temporally varied range of phe-
notypes. A complete picture of theMeCP2protein includes its
roles at various life stages, so as to inform our evolving con-
cept of RTT progression in patients and potential phenotypic
reversibility.
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